Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | BRD2 | P25440 | 5/20 | 0.59 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.59 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CCL2 | P13500 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odm-207 SCHEMBL29732197 | 1.00 | BRD4 (0.60) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL20547340 | 0.95 | BRD4 (0.61) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359487 | 0.92 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL20547091 | 0.92 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896785 | 0.90 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359646 | 0.90 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896774 | 0.90 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896864 | 0.90 | BRD4 (0.56) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359548 | 0.90 | BRD4 (0.55) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16905847 | 0.89 | BRD4 (0.60) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| WO-2025054356-A1 | BET INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-4480494-A1 | COMPOSITION FOR USE IN TREATMENT OF CANCER, INFLAMMATORY DISEASES, OR OBESITY, AND USE THEREOF | National University Corporation Tokyo Medical and Dental University (JP) | 2024-12-25 | — | — | EP | claimed |
| US-20240325402-A1 | MOMELOTINIB COMBINATION THERAPY | SIERRA ONCOLOGY LLC | 2024-10-03 | — | — | US | claimed |
| CN-117794546-A | Molotinib combination therapy | 葛兰素史密斯克莱有限责任公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2023157891-A1 | COMPOSITION FOR USE IN TREATMENT OF CANCER, INFLAMMATORY DISEASES, OR OBESITY, AND USE THEREOF | 国立大学法人 東京医科歯科大学 | 2023-08-24 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| US-20220204493-A1 | CRYSTALLINE FORM OF A BET-INHIBITOR AND MANUFACTURE THEREOF | AURIGENE ONCOLOGY LIMITED (IN) | 2022-06-30 | — | — | US | claimed |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | claimed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | claimed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | claimed |
| EP-3092227-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-11-16 | — | — | EP | claimed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| EP-3092227-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325402-A1 | MOMELOTINIB COMBINATION THERAPY | TPMT, ABL1, JAK1 | BRD4 1296/4885CYP3A4 3835/4885CYP2C9 3893/4885 |
| US-20220204493-A1 | CRYSTALLINE FORM OF A BET-INHIBITOR AND MANUFACTURE THEREOF | BET1, BRD4, TMPO | BRD4 2/4885CYP3A4 2358/4885CYP2C9 3764/4885 |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | BRD4 4/4885CYP3A4 1942/4885CYP2C9 1528/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | BRD4 163/4885CYP3A4 4477/4885CYP2C9 4228/4885 |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | BRD4 4/4885CYP3A4 1942/4885CYP2C9 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.